Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lenz

Showing results (301-310 of 367) with videos related to

Pageof 37
Sort By:
Obstetrics and Gynecology|October 11, 2017
Ovarian Vein Thrombosis: Incidence of Recurrent Venous Thromboembolism and SurvivalCharles J Lenz, Waldemar E Wysokinski, Stanislav Henkin, et al.
The Pharmacogenomics Journal|June 12, 2013
Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapyL Benhaim, A Gerger, P Bohanes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survivalH J Lenz, C G Leichman, K D Danenberg, et al.
The Pharmacogenomics Journal|March 11, 2015
Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastasesS Stremitzer, Y Sunakawa, W Zhang, et al.
The Pharmacogenomics Journal|February 11, 2015
LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapyJ Szkandera, S Herzog, M Pichler, et al.
Cancer Letters|October 6, 1997
Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapyM Kornmann, K H Link, H J Lenz, et al.
Mayo Clinic Proceedings|December 9, 2017
Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical LocationDawid T Janczak, Malgorzata K Mimier, Robert D McBane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivityJ F Ju, D Banerjee, H J Lenz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2011
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancerM J Labonte, P M Wilson, D Yang, et al.
The Pharmacogenomics Journal|December 24, 2014
Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapyM K H Maus, D L Hanna, C L Stephens, et al.
Pageof 37

Showing results (301-310 of 367) with videos related to

Sort By:
Pageof 37
Obstetrics and Gynecology|October 11, 2017
Ovarian Vein Thrombosis: Incidence of Recurrent Venous Thromboembolism and SurvivalCharles J Lenz, Waldemar E Wysokinski, Stanislav Henkin, et al.
The Pharmacogenomics Journal|June 12, 2013
Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapyL Benhaim, A Gerger, P Bohanes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survivalH J Lenz, C G Leichman, K D Danenberg, et al.
The Pharmacogenomics Journal|March 11, 2015
Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastasesS Stremitzer, Y Sunakawa, W Zhang, et al.
The Pharmacogenomics Journal|February 11, 2015
LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapyJ Szkandera, S Herzog, M Pichler, et al.
Cancer Letters|October 6, 1997
Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapyM Kornmann, K H Link, H J Lenz, et al.
Mayo Clinic Proceedings|December 9, 2017
Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical LocationDawid T Janczak, Malgorzata K Mimier, Robert D McBane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivityJ F Ju, D Banerjee, H J Lenz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2011
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancerM J Labonte, P M Wilson, D Yang, et al.
The Pharmacogenomics Journal|December 24, 2014
Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapyM K H Maus, D L Hanna, C L Stephens, et al.
Pageof 37